List of Xospata drug patents
Xospata is owned by Astellas.
Xospata contains Gilteritinib Fumarate.
Xospata has a total of 3 drug patents out of which 0 drug patents have expired.
Xospata was authorised for market use on 28 November, 2018.
Xospata is available in tablet;oral dosage forms.
Xospata can be used as treatment of acute myeloid leukemia (aml).
Drug patent challenges can be filed against Xospata from 2022-11-28.
The generics of Xospata are possible to be released after 01 July, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8969336 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jan, 2031
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9487491 | ASTELLAS | Diamino heterocyclic carboxamide compound |
Jul, 2030
(7 years from now) | |
| US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
| New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
NCE-1 date: 2022-11-28
Market Authorisation Date: 28 November, 2018
Treatment: Treatment of acute myeloid leukemia (aml)
Dosage: TABLET;ORAL
XOSPATA family patents
7
Japan
6
United States
3
Hungary
3
European Union
2
Denmark
2
Mexico
2
Hong Kong
2
Slovenia
2
Lithuania
2
Russia
2
Norway
2
Croatia
2
Portugal
2
Cyprus
2
Spain
2
Korea, Republic of
2
Poland
2
Taiwan, Province of China
2
RS
2
China
2
Canada
1
Israel
1
South Africa
1
Australia
1
Philippines
1
Brazil
1
Netherlands
1
San Marino
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic